Neurocrine halts development of schizophrenia drug as trial fails - Health News - News 247

Jump to content

Existing user? Sign In
Sign In

Remember me Not recommended on shared computers

Forgot your password?
Sign Up

ADS

ADS

ADS

ADS

Neurocrine halts development of schizophrenia drug as trial fails
(0 reviews)
By Author

September 13
Share
https://news247.center/news/health-news/neurocrine-halts-development-of-schizophrenia-drug-as-trial-fails-r38/

Followers 0
The company said the drug, luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance, due to a large variability in the cognitive measures across the patients and a potential imbalance in their baseline characteristics.
Source Link
Share
https://news247.center/news/health-news/neurocrine-halts-development-of-schizophrenia-drug-as-trial-fails-r38/
Followers 0
Go to articles

User Feedback
- 0 Reviews
- 0 Comments
Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Your email address Required

This will not be shown to other users.

Your rating Required

1 2 3 4 5

Your review Required

Add a review...

× Pasted as rich text.   Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded.   Display as a link instead

× Your previous content has been restored.   Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

×

Desktop

Tablet

Phone
ADS

ADS

×

News
- Back
- News
- Arts & Lifestyle
- Finance
- Gaming
- Health
- History
- Politics
- Science
- Sports
- Technology
- World
Forums

×

Create New...

Important Information

Cookie Consent & Terms We use cookies to enhance your experience on our site. By continuing to browse our website, you agree to our use of cookies as outlined in our We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.. Please review our Terms of Use, Privacy Policy, and Guidelines for more information.